The Next Wave of Immune Cell Therapy From CAR T to eTCR: New immune cell therapies push beyond blood cancers By April 1, 2026 18 min Dana-Farber Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Poll Top Institutions Clinical Report: The Next Wave of Immune Cell Therapy Overview{'add': 'Include additional examples of genetic mutations targeted by eTCR therapies.'} Background{'add': 'Discuss specific limitations of traditional treatments for solid tumors.'} Data Highlights{'remove': 'Placeholder text and replace with qualitative insights.'} Key Findings{'rephrase': 'Ensure clarity and direct support from the source.'} Clinical Implications{'expand': 'Detail specific patient selection criteria.'} Conclusion{'add': 'Mention future research directions.'} References The ASCO Post, 2016 -- Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored The ASCO Post, 2019 -- The Future of Immunotherapy: Building on Checkpoint Blockade The ASCO Post, 2017 -- The Immune System: Deciphering Recent Advances FDA -- FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma FDA -- FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma The ASCO Post — Combination Immunotherapy for Lung Cancer: The Wave of the Future FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma | FDA FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma | FDA Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting | Journal of Hematology & Oncology | Full Text CRISPR-Cas9–Edited Tumor-Infiltrating Lymphocytes in Metastatic Colorectal Cancer - The ASCO Post
